Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice

Experimental Parasitology

Volumn 131, Issue 3, 2012, Pages 292-299

  Aditya, N P ^a   Chimote, Geetanjali ^b   Gunalan, Karthigayan ^c   Banerjee, Rinti ^b   Patankar, Swati ^b   Madhusudhan, Basavaraj ^a  

^a DAVANGERE UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Combination therapy; Curcuminoids; Drug delivery; Liposomes; Malaria; Parasitemia

Indexed keywords

ARTEETHER; CURCUMINOID DERIVATIVE; LIPOSOME; PLACEBO; POLYPHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; EXPERIMENTAL MOUSE; FILM; HYDRATION; LIPOSOMAL DELIVERY; MONOTHERAPY; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; SURVIVAL RATE; SUSTAINED RELEASE FORMULATION;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CURCUMA; CURCUMIN; DISEASE MODELS, ANIMAL; HEMOLYSIS; HUMANS; LIPOSOMES; MALARIA; MICE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; PLASMODIUM BERGHEI; POLYPHENOLS;

ANIMALIA; MUS; PLASMODIUM BERGHEI;

EID: 84862582534     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.04.010     Document Type: Article

References (37)

1. Aditya N.P., Waree T., Patankar S. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Coll. Surf. B 2010, 81:263-273.
2. Aditya N.P., Patankar S., Madhusudhan B. Artemether loaded lipid nanoparticles produced by modified-thin film hydration: pharmacokinetics, toxicological and in vivo antimalarial activity. Eur. J. Pharm. Sci. 2010, 40:448-455.
3. Ajay K.A., Puri A., Haq W. Enhanced immunostimulant activity and protective effect of a synthetic lipopeptide after liposomization against Plasmodium berghei infection in mice. J. Dug Target 2001, 9(4):231-239.
4. Arbiser J.L., Klauber N., Rohan R. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. 1998, 4:376-383.
5. Autian, J., 1975. Biological model systems for the testing of the toxicity of biomaterials. In: Kronenthal, R.L, Oser, Z., Martin, E. (Eds.), Polymer Science and Technology, Polymers in Medicine and Surgery, vol. 8. Plenum, New York, pp. 181.
6. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the swollen phospholipids. J. Mol. Biol. 1965, 13:238-252.
7. Bordmann W., Rudin N.F. Immunization of mice with phosphatidylcholine drastically reduces the parasitemia of subsequent Plasmodium chabaudi chabaudi blood-stage infections. Immunology 1998, 94:35-40.
8. Chimanuka B., Gabriels M., Detaevernier M.R., et al. Preparation of β-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitemia in Plasmodium chabaudi malaria-infected mice. J. Pharm. Biomed. Anal. 2002, 28:13-22.
9. Christopher I., Samantha O., Don J.L. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61:1058-1064.
10. Cong, W., Liu, Q., Chen, X., et al., 2010. Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev. Ind. Pharm. 36(10), 1186-1194.
11. Crommelin D.J.A., Eling W.M.C., Steerenberg P.A., et al. Liposome and immunoliposome for controlled release or site specific delivery of anti-parasitic drugs and cytostatics. J. Controlled Release 1991, 161:47-154.
12. Date A.A., Medha D.J., Vandana B.P. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59(6):505-521.
13. Dandekar P.P., Ratnesh H.J., Sushant P., et al. Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J. Pharm. Sci. 2010, 99(12):4992-5010.
14. Golenser J., Domb A., Teomim D., et al. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J. Pharmacol. Exp. Ther. 1997, 281:1127-1135.
15. Grun J.L., Weidanz W.P. Antibody-independent immunity to reinfection malaria in B-cell-deficient mice. Infect. Immun. 1983, 41:197-1204.
16. Gwatkin D.R., Guillot M. The Burden of Disease Among ihe Global Poor 2000, The World Bank, Washington, USA.
17. Jayaprakasha G.K., Lingamullu J.M.R., Kunnumpurath K.S. Improved HPLC method for the determination of curcumin, demethoxycurcumin and bisdemethoxycurcumin. J. Agric. Food Chem. 2002, 50:3668-3672.
18. Korenromp E.L., Williams B.G., Gouws E., et al. Measurement of trends in childhood malaria nirtakuty ub Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect. Dis. 2003, 3:349-358.
19. Kunwar A., Barik A., Pandey R., et al. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim. Biophys. Acta 2006, 1760(10):1513-1520.
20. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
21. Lukita-Atmadja W., Ito Y., Baker G.L., et al. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 2002, 17:399-403.
22. Matthew C., Amy C., Robyn T.B., et al. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J. Surg. Res. 2000, 89:169-175.
23. Nandakumar, D.N., Arun, V.N., Vathsala, P.G., 2006. Curcumin-artemisinin combination therapy for malaria. Antimicrob. Agents Chemother. 1859-1860.
24. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27:486-494.
25. Peeters P.A.M., Huiskamp C.W.E., Eling W.M.C., et al. Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology 1989, 98:381-386.
26. Pirson P., Steiger R.F., Trouet A., et al. In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes. Ann. Trop. Med. Parasitol. 1980, 74:383-391.
27. Ruby A.J., Kuttan G., Babu K.D., et al. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995, 94:79-83.
28. Reddy R.C., Vathsala P.G., Keshamouni V.G., et al. Curcumin for malaria therapy. Biochem. Biophys. Res. Commun. 2005, 326:472-474.
29. Snow R.W., Guerra C.A., Noor A.M., et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
30. Sharma R.A., Gescher A.J., Steward W.P. Curcumin: the story so far. Eur. J. Cancer 2005, 41:1955.
31. Singh S., Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anti. Canc. Agents Med. Chem. 2006, 6:259.
32. Savita, B., Georg, F., Sheetal, S, et al., 2007. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): A novel strategy for human cancer therapy. J. Nanobiotechnol. Available from URL: http://www.jnanobiotechnology.com/content/5/1/3.
33. Sou K., Inenaga S., Takeoka S., et al. Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 2008, 352(1-2):287-293.
34. Taylor-Robinson A.W., Phillips R.S. B cells are required for the switch from Thl- to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect. Immun. 1994, 62:2490-2498.
35. Tonnesen H., Solveig K., Leonid N.G. Studies on curcumin and curcuminoids: XXV. Inhibition of primaquine-induced lysis of human red blood cells by curcumin. Int. J. Pharm. 1994, 110:161-167.
36. Targett G.A.T. Malaria: drug use and the immune response. Parasitology 1992, 105:61-70.
37. Varalakshmi Ch., Mubarak A.A., Pardhasaradhi B.V.V., et al. Immunomodulatory effects of curcumin: in-vivo. Int. Immunopharmacol. 2008, 8(5):688-700.